Genetic Testing & Personalized Medicine
•29 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (29)
%
| Company | Market Cap | Price |
|---|---|---|
|
Genetic testing and personalized medicine capabilities are core to Labcorp, including Invitae integration expanding genetic screening.
|
$23.26B |
$277.88
-0.11%
|
|
Natera's core offerings are genetic testing and personalized medicine delivered via cfDNA-based tests (Signatera, Panorama, Horizons, Prospera).
|
$22.07B |
$161.61
+0.94%
|
|
Illumina’s sequencing platforms enable genetic testing and personalized medicine applications.
|
$14.86B |
$93.86
-2.73%
|
|
Reproductive genetic testing in embryos leveraging AI aligns with Genetic Testing & Personalized Medicine.
|
$14.02B |
$69.75
-0.53%
|
|
EXAS's core business is genetic testing and personalized cancer diagnostics (e.g., Oncotype DX, Oncodetect, Cancerguard, BLUE-C-based tests), fitting Genetic Testing & Personalized Medicine.
|
$11.01B |
$58.34
-2.11%
|
|
Core business: diagnostic genetic testing services (exome/genome) and personalized medicine data assets.
|
$3.47B |
$121.72
-4.53%
|
|
Veracyte's core offering is genetic testing and biomarker-driven patient stratification across cancer types (Decipher Prostate, Afirma, Prosigna, MRD, Percepta).
|
$2.73B |
$34.80
-0.66%
|
|
Galleri involves genetic testing and personalized health insights from cfDNA methylation, aligning with Genetic Testing & Personalized Medicine.
|
$2.38B |
$66.13
-7.38%
|
|
NeoGenomics' core business is cancer diagnostic testing including NGS, FISH, cytogenetics, flow cytometry, IHC, and MRD assays, central to precision oncology and biomarker-driven treatment decisions.
|
$1.17B |
$9.10
+1.56%
|
|
dd-cfDNA and gene expression tests are core genetic testing and personalized medicine offerings.
|
$801.24M |
$14.39
-2.64%
|
|
Core genetic testing and personalized medicine platform, including hereditary cancer risk, pharmacogenomics, oncologic tumor profiling, and prenatal testing.
|
$709.77M |
$7.72
+0.78%
|
|
Core genetic testing and personalized medicine platform including exome/genome sequencing, carrier screening, and germline tests.
|
$685.29M |
$22.51
-1.01%
|
|
Tests rely on gene expression profiling and personalized risk stratification, aligning with genetic testing and personalized medicine.
|
$666.37M |
$23.08
-3.11%
|
|
HiFi sequencing enables genetic testing and personalized medicine applications, aligning PacBio with the genetic testing/personalized medicine theme.
|
$426.12M |
$1.42
-8.97%
|
|
Genetic testing and personalized medicine analytics enabled by SOPHiA DDM platform.
|
$277.71M |
$4.18
-7.32%
|
|
CircleDNA genetic testing platform constitutes core consumer genetics and personalized medicine offerings.
|
$169.77M |
$13.89
-3.94%
|
|
Company's diagnostic tests align with genetic testing and personalized medicine in transplantation and oncology.
|
$111.25M |
$3.89
+2.37%
|
|
Epigenetic biomarker diagnostics align with Genetic Testing & Personalized Medicine thematic coverage.
|
$47.81M |
$0.46
-10.75%
|
|
HemeScreen genetic panels and other genetic testing align with Genetic Testing & Personalized Medicine.
|
$28.79M |
$19.04
-7.65%
|
|
Core offering: MSC Lung Test and StemPrintER are genomic tests enabling personalized cancer diagnostics/prognostics (Genetic Testing & Personalized Medicine).
|
$23.64M |
$1.47
+2.85%
|
|
Nebula Genomics and DNA Expand platforms involve genetic testing and personalized health data services.
|
$21.85M |
$0.53
+1.29%
|
|
GPS and Germline testing align with Genetic Testing & Personalized Medicine.
|
$11.13M |
$4.08
-7.06%
|
|
Epigenetic biomarker testing aligns with genetic testing & personalized medicine.
|
$8.05M |
$1.05
-3.67%
|
|
CDIO engages in Genetic Testing & Personalized Medicine via its genetic/epigenetic tests and data-driven insights for cardiovascular risk management.
|
$7.22M |
$4.15
-7.37%
|
|
Ludwig's core offering centers on mRNA biomarker analysis for cancer detection, aligning with Genetic Testing & Personalized Medicine.
|
$6.79M |
$0.04
|
|
BNGO operates in the genetic testing/personalized genomics space via its diagnostic services and platform, enabling genetic analysis workflows.
|
$6.76M |
$2.01
-1.95%
|
|
Genetic Testing & Personalized Medicine services via DNA genotyping private label offerings.
|
$6.62M |
$0.03
|
|
Core genetic testing and personalized medicine diagnostics (ThyGeNEXT, ThyraMIR, RespriDx, PathFinderTG).
|
$3.94M |
$0.90
+5.28%
|
|
ColoAlert uses genetic biomarkers with PCR-based molecular diagnostics for colorectal cancer detection, aligning with Genetic Testing & Personalized Medicine.
|
$1.02M |
$1.60
|
Loading industry metrics...
Loading comparison data...
